<DOC>
	<DOCNO>NCT02889367</DOCNO>
	<brief_summary>The purpose study determine relationship plasma concentration odalasvir change QT interval / QTc interval ( QT correct heart rate ) use exposure-response ( ER ) analysis .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Effect Cardiac Repolarization Odalasvir Administered Single Dose Tablet Under Fed Conditions Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Participant must sign informed consent form ( ICF ) indicate understands purpose , procedure require , study willing participate study Participant must willing able adhere prohibition restriction specify protocol Participant must healthy basis physical examination , medical history , vital sign perform screen Participant must blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Participant must normal 12lead electrocardiogram ( ECG ) echocardiogram must healthy basis clinical laboratory test perform screen Participant must nonsmoker least 6 month prior study drug administration Participant history clinically relevant heart rhythm disturbance include atrial , junctional , reentry , ventricular tachycardia , heart block Participant unusual T wave morphology ( bifid T wave ) likely interfere QTc measurement Participant past history : Sick sinus syndrome , Cardiac arrhythmia ( example , extrasystolic rhythms tachycardia rest ) . Isolated extrasystolic beat exclusionary , Risk factor associate Torsade de Pointes ( TdP ) hypokalemia , Family history short/long QT syndrome , Sudden unexplained death ( include sudden infant death syndrome ) firstâ€‘degree relative ( , sibling , offspring , biological parent ) Participant skin condition likely interfere ECG electrode placement adhesion Participant breast implant history thoracic surgery likely cause abnormality electrical conduction thoracic tissue Participant history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participant receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 30 day within period le 10 time drug 's halflife , whichever longer , plan administration study drug , currently enrol investigational study Participant history human immunodeficiency virus ( HIV ) 1 HIV2 infection positive , test positive HIV1 HIV2 screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>